Company intelligence / Profile preview

Macrogenetics

Rockville, Maryland, United States

Ownership: Private
Employees: ~240
Development stage: Other

Overview

MacroGenics has FDA approval for Margenza (margetuximab) in metastatic HER2-positive breast cancer, ZYNYZ for cancer, and TZIELD for early-stage Type 1 diabetes. Other programs are in Phase 1-3 clinical trials for various cancers.

Therapeutic areas: OncologyEndocrinology
Modalities: Monoclonal antibodyAntibody-drug conjugateBispecific monoclonal antibody
Industry: Biotech

Partnerships

Genentech (partnered for antibody therapeutics)Partnerships with various large pharma companies for R&D and commercial rights

Beyond the preview

Go deeper on Macrogenetics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Macrogenetics.

Explore the full profile